Please try another search
ZURICH (Reuters) - Novartis (SIX:NOVN) is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday. Around 440...
(Reuters) -Drugmaker Novartis AG (SIX:NOVN) said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer...
By Ludwig Burger FRANKFURT (Reuters) -Novartis reported a 6% gain in adjusted net income on Wednesday that fell short of the market view, as corporate expenses surpassed expectations built up by a...
By Gnaneshwar Rajan and Gursimran Mehar (Reuters) -The U.S. health regulator on Monday asked a host of drugmakers, including Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ) and Novartis...
ZURICH (Reuters) -Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million. The drug is interchangeable...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Merck's drug belzutifan for a type of kidney cancer. The drug, branded as Welireg, is used to treat patients with renal cell...
By David Gaffen (Reuters) - A broad swath of global industrial and consumer bellwethers reported stronger-than-expected earnings in their most recent quarter, as resilient spending patterns kept...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review